Teva picks outsider to steer next growth phase
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has opted for a company outsider to lead it to the next level in the company's development. Teva, which has seen its sales grow from $8.4 billion in 2006 to an anticipated $22 billion in 2012, has picked Dr Jeremy Levin to replace Shlomo Yanai as president and CEO of the Israeli company.